Prevention of rabies virus infection in dogs by a recombinant canine adenovirus type-2 encoding the rabies virus glycoprotein
Prevention of rabies virus infection in dogs by a recombinant canine adenovirus type-2 encoding the rabies virus glycoprotein
复制标题
DOI：
10.1016/j.micinf.2005.11.007
复制
发表时间：
2006-04-01
影响因子：
5.8
通讯作者：
Xiao, Yueqiang
中科院分区：
文献类型：
--
作者：
Hu, Rongliang;Zhang, Shoufeng;Xiao, Yueqiang
安全有效的疫苗接种对于预防动物狂犬病非常重要。尽管已经开发出几种基因工程狂犬病疫苗，但很少有获得使用许可，主要是由于生物安全问题或在动物模型中疗效不佳。在本文中，我们描述了表达狂犬病病毒糖蛋白（SRV9株）的具有复制能力的重组犬2型腺病毒（SRV9株）的构建和表征，该策略与之前报道的策略不同，即通过一系列严格的基因克隆步骤产生携带糖蛋白cDNA的重组基因组，通过将重组基因组转染到犬肾细胞系MDCK中获得感染性重组病毒。这种重组病毒 CAV-E3 Delta-CGS 被皮下注射到狗体内。所有接种疫苗的狗在一次接种后都产生了有效的中和抗体，并且在加强注射后产生了更强的记忆免疫反应。免疫犬可以在 60,000 只小鼠 LD50 CVS-24 的攻击下存活下来，该疫苗对所有未免疫犬都具有致命性，与传统疫苗相当。免疫力可持续数月，并具有保护水平的中和抗体。这种重组病毒将成为减毒和灭活狂犬病疫苗的替代品，并且有望用于对狗进行狂犬病免疫。 (c) 2005 年爱思唯尔 SAS。版权所有。
Safe and effective vaccination is important for rabies prevention in animals. Although several genetically engineered rabies vaccines have been developed, few have been licensed for use, principally due to biosafety concerns or due to poor efficacy in animal models. In this paper, we describe the construction and characterization of a replication-competent recombinant canine adenovirus type-2 expressing the rabies virus glycoprotein (SRV9 strain) by a different strategy from that reported previously, i.e., the recombinant genome carrying the glycoprotein cDNA was generated by a series of strictly gene cloning steps, infectious recombinant virus was obtained by transfecting the recombinant genome into a canine kidney cell line, MDCK. This recombinant virus, CAV-E3 Delta-CGS, was subcutaneously injected into dogs. All vaccinated dogs produced effective neutralizing antibodies after one inoculation and a stronger anamnestic immune response was produced after booster injection. The immunized dogs could survive the challenge of 60,000 mouse LD50 CVS-24, which is lethal to all unimmunized dogs and is comparable to the conventional vaccines. The immunity lasts for months with a protective level of neutralizing antibody. This recombinant virus would be an alternative to the attenuated and the inactivated rabies vaccines and be prospective in immunizing dogs against rabies. (c) 2005 Elsevier SAS. All rights reserved.